Lung fibrosis follows COVID-19 pneumonia in 2026.
Post-severe acute respiratory syndrome coronavirus 2 interstitial lung disease covers everything from resolving inflammation to persistent fibrosis, Cureus reported.
This isn’t just about recovery; a subset of patients develop progressive pulmonary fibrosis, or PPF, years after the initial infection.
The diagnostic challenge lies in separating late-stage post-infectious changes from newly emerging, unclassified PPF, as noted in the report.
A 57-year-old man first faced severe COVID-19 pneumonia in April 2020, and later developed progressive restrictive lung disease despite initial stability.
For this patient, initial radiological stability around 2024 gave way to worsening hypoxemia after a pneumonia episode in March 2025.
Another case, a 64-year-old never-smoker, showed initial improvement after COVID-19 in 2021, only for new fibrotic changes, including subpleural honeycombing, to appear in 2025.
“PPF may develop several years after severe COVID-19 pneumonia, even with initial radiological improvement or prolonged stability,” said the authors of the report.
These examples show the unpredictable, heterogeneous nature of pulmonary abnormalities following severe COVID-19 infection.
For those who survived severe COVID-19 pneumonia but develop interstitial lung disease, chronic disability remains a major human and economic stake.
PPF is defined by clinical, physiological, and radiological progression over the past year, requiring at least two of three criteria.
The differential diagnosis for the 57-year-old included asbestosis, GERD-associated microaspiration, and primary lung cancer, given his history of asbestos exposure as a plumber.
Because histology was inconclusive in both cases, antifibrotic medication nintedanib was initiated, and both patients were referred for lung transplant evaluation.
The data confirms that prolonged stability doesn’t guarantee a stable outcome, demanding continued evaluation with lung function testing and serial high-resolution computed tomography.
The evidence suggests that early referral for lung transplant evaluation is necessary for those who progress despite medical therapy.
The development of diffuse alveolar damage, organizing pneumonia, nonspecific interstitial pneumonia, and usual interstitial pneumonia are common clinical descriptions of post-COVID-19 ILD, though their temporal relationship is unknown.
Some might argue that aggressive antifibrotic use in early, unconfirmed cases risks unnecessary medical intervention, but the progression shown in both men argues against waiting for definitive pathology.
For patients facing this progression, the necessity of managing restrictive ventilatory impairment, marked by declines in forced vital capacity and diffusing capacity, demands integrated care across pulmonology and cardiology, especially when assessing preserved left ventricular function.
The study’s presentation of these two cases illustrates the breadth of pulmonary sequelae, moving beyond simple acute infection recovery toward chronic, progressive disease management, as detailed in the Cureus report.
The 64-year-old patient, a never-smoker, demonstrated initial radiological improvement after corticosteroid treatment, a pattern sharply contrasted by the 57-year-old’s continued decline even after immunosuppressive therapy with mycophenolate mofetil.
Official guidance on managing severe COVID-19 sequelae can be found through established health bodies like the Centers for Disease Control and Prevention.
The question remains what long-term, standardized, non-invasive biomarkers can reliably predict the transition from stable post-infectious changes to true progressive pulmonary fibrosis.